Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
Healthcare
$28.76 +1.50%
+$0.50 today
- Market cap
- $1.72B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
52W Low $22.24High $46.00
Volume 0.47M
Average 1.11M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$372.98M
FY 2025 · Annual
Investing Cash Flow
$377.18M
FY 2025 · Annual
+3.8% YoYFinancing Cash Flow
$8.68M
FY 2025 · Annual
-39.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (356.51M) | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Depreciation & Amortization | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.51M | 49.3M | 44.77M | 42.85M | 52.55M |
| Change in Working Capital | (36.82M) | (16.43M) | (19.06M) | (19.77M) | (33.04M) |
| Accounts Receivables | (4.38M) | (2.21M) | (604K) | (1.3M) | (6.47M) |
| Inventory | 0 | (8.49M) | (10.58M) | (8.54M) | (5.3M) |
| Accounts Payables | 1.86M | 3.44M | (8.73M) | 6.6M | 1.75M |
| Other Working Capital | (34.31M) | (9.17M) | 864K | (16.53M) | (23.02M) |
| Other Non-Cash Items | (76.74M) | (119.1M) | 23.69M | (1.09B) | 15.12M |
| Operating Cash Flow | (407.32M) | (309.48M) | (296.06M) | (389.84M) | (372.98M) |
| Capital Expenditures | (5.74M) | (4.88M) | (999K) | (1.69M) | (4.32M) |
| Acquisitions (Net) | 0 | 132.75M | 0 | 40K | 0 |
| Purchases of Investments | (1.38B) | (1.03B) | (417.93M) | (1.54B) | (641.76M) |
| Sales of Investments | 829.8M | 1.15B | 674.68M | 818.38M | 1.03B |
| Other Investing Activities | 1.8B | 0 | (16.18M) | 1.09B | (10M) |
| Investing Cash Flow | 1.25B | 243.26M | 239.58M | 363.44M | 377.18M |
| Debt Repayment | (578K) | (331K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 2.68M | 5.43M | 14.44M | 8.68M |
| Common Stock Repurchased | (802.49M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.3M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (765.77M) | 2.35M | 5.43M | 14.44M | 8.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 75.69M | (63.87M) | (51.05M) | (11.96M) | 12.88M |
| Free Cash Flow | (413.06M) | (314.36M) | (297.06M) | (391.53M) | (377.29M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$412.8M
+ D&A$5.2M
+ Stock-Based Comp$52.6M
+ Deferred Tax$0
- Working Capital-$33.0M
+ Other Non-Cash$15.1M
= Operating Cash Flow-$373.0M
- Capex-$4.3M
= Free Cash Flow-$377.3M
Analysis
FY2025 free cash flow is -$377.3M. FCF conversion is 91.4% of net income. Operating cash flow was -$373.0M, with capex of -$4.3M. The largest bridge item is Stock-Based Comp at $52.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
Does AGIO generate free cash flow?
Agios Pharmaceuticals, Inc. (AGIO) generated -$377.29M of free cash flow in fiscal 2025.
How much operating cash flow does AGIO produce?
Operating cash flow was -$372.98M, before capital expenditures of $4.32M.
Continue the stock analysis
Jump to another research area for this company.